INTRODUCTION

Doxorubicin is one of the most one effective antitumor drugs in human cancers, comprising “acute lymphoblastic leukemia, breast carcinoma, ovarian carcinoma, and hepatocellular carcinoma (HEP2)” [1]. However, side effects make clinical application which is limited, and to overcome them, there should be new research method by changing biological distribution to target sites. Nanocomposites opened new way to treatment by reducing side effects and using them in chemotherapy [2]. Zinc oxide (ZnO) nanocomposites can make significant contributions to the development of approaches of drug delivery in cancer and provide a platform for combined therapeutics with subsequent monitoring of response [3] are high efficient and non-toxic in addition to being stable at PH=7, but solubility increases at PH > 6, and for easy arrived to the targeted sites[4]. This presses causes mitochondrial weaken which are produces " reactive oxygen species (ROS)" lipid peroxidation and DNA damage [5-7]. ZnO NPs are interacted with cancer cells rises from normal level, resulting in zinc-mediated protein activity disequilibrium. This affects a wide range of crucial cellular processes, including DNA replication, DNA damage repair, apoptosis, oxidation stress, electron transport chain, and cellular homeostasis, rendering cytotoxicity toward the cell [8]. ZnO-cadmium sulfide (CdS) NPs are important compounds for use in biomedical research, because of higher activity to anticancer and antimicrobial activities. In addition, it has been successfully used as drug delivery for loading and transport drugs to infected sites [9]. Several studies have suggested an increase in in vitro cytotoxicity with anaphase ZnO compared to micron-sized ZnO for several types of cancer including glioma, breast, bone, colon, and leukemias and lymphomas [10,11]. These studies showed the high degree of selective cancer cells, and killing them was depended on the proliferation status of cells, with rapidly dividing cells being the most susceptible [12]. Based on a growing body of evidence, ROS production is proposed as a key cytotoxic mechanism of ZnO NPs leading to cell death through an apoptotic mechanism [13]. ZnO exhibits biocompatibility. Therefore, Arakelova et al. [14] studied the action of ZnO NPs against MCF7 (human breast cell) and A549 (human lung cancer).

METHODS

Zinc acetate dehydrate, oxalic acid, and toluene were provided from China. Olic acid was supplied from Germany; thiocetamide and cadmium nitrate were purchased from HANNOVER. O-sylene was supplied from Washington.

Preparation of ZnO NPs

ZnO NPs were prepared by solving 22 g of zinc acetate with 600 ml ethanol and heated to 60°C for 30 min; 25.2 g oxalic acid was solved with 400 ml ethanol and heated to 50°C and then mixed with the solvent above with the continuous stirring for 4 h then drying the thick solution at 80°C for 24 h to obtain nanopowder ZnO [15]. ZnO NPs were modified with oleic acid, as coupling agents, to modify their surface properties and make them more hydrophobic dispersible in the organic area.

Preparation of ZnO/CdS NPs

The ZnO/CdS NPs were synthesized by immersed ZnO NPs into the clear reactant solution containing thiocetamide (0.01M) C6H5NS(0.01M) and Cd(NO3)2 at room temperature for 15 min. A yellow color precipitate of ZnO/CdS was observed by adsoring of CdS on the surface of ZnO NPs. A yellow sample was washed and filtrated by deionized water to remove the surface residue and finally dried at 90°C [16].

Characterization

ZnO NPs were characterized by scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDS), atomic force microscopy, Fourier transform infrared spectroscopy (FT-IR) and X-ray diffraction (XRD).

SEM

SEM was used for observing the morphology of synthesized samples. Fig. 1 shows the SEM images of ZnO naked and modified NPs surface. The results showed highly agglomeration of ZnO NPs due to the surface energy that tends to clump together in large particles, and this agrees with the results of Xin [16]. It was found that the surface-modified...
ZnO NPs have reduced the agglomeration by reducing the energy of the surface. The results showed that the ZnO NPs were dispersed homogeneously after modification. Fig. 2 shows that the particle size was increased due to adhering of CdS NPs to the surface of ZnO NPs; the larger particles were the aggregates of smaller CdS NPs when a multilayer of CdS NPs was formed on the surface ZnO NPs.

EDS
The spectrum of EDS crystalline ZnO NPs is shown in Fig. 3. The purity of ZnO is 100% since there are no elements appeared in the spectrum and element analysis agrees with the researches [18].

XRD analysis
The XRD patterns of naked and unmodified ZnO NPs at a diffracted angle (30º–70º) are illustrated in Fig. 4a; a crystalline peak appeared which indicates crystalline structure at 2θ=34, while a peak for modified ZnO at 2θ=36.569. This indicates that crystalline material is prepared which agrees with the results of Zhang and Yang [19]. From the X-ray test (Fig. 4) of ZnO naked and modified NPs at a diffracted angle (30º–70º), a crystalline peak appeared which indicates crystalline structure at 2θ=34 and also a peak for modified ZnO at 2θ=36.569. This indicates that crystalline material is prepared which agrees with the results of the Zhang and Hong [19,20]. XRD pattern of a ZnO/CdS core shell NPs is shown in Fig. 4c where the diffraction peaks can be indexed to the spherical ZnO/ CdS core shell structure. In total, seven diffraction peaks corresponding to the (100), (002), (101), (102), (110), (103), (200), (112) and (201) were related to the hexagonal crystal structure of ZnO [21].

Five human cancer cell lines namely; Hepatocellular carcinoma (HEPG-2), Mammary gland (MCF-7), Epdermoid Carcinoma (HEP2), Colorectal carcinoma (HCT-116) and Rabdomyosarcoma (RD) were used to determine the antitumor activity of ZnO and ZnO/CdS NPs. The cell lines were obtained from ATCC through Holding Company for Biological Products and Vaccines (VACSERA), Cairo, Egypt. Doxorubicin was used as a standard anticancer drug for comparison.

Chemical reagents
RPMI-1640 medium, MTT and DMSO (Sigma co., St. Louis, USA), Fetal Bovine serum (GIBCO, UK) were used as reagents.

Antioxidant assays by ABTS
Antioxidant activity screening assay by ABTS method: For each of the investigated samples, 2 ml of ABTS solution (60 μM) was added to 3 ml MnO₂ suspension (25mg/ml), in aqueous phosphate buffer solution (pH 7, 0.1 M). The mixture was shaken, centrifuged, and filtered and the absorbance of the resulting green blue solution (ABTS radical solution) at 734 nm was adjusted to approx. ca. 0.5. Then, 50 μl of 2 mμ solution of the tested sample in spectroscopic grade MeOH:phosphate buffer (1:1) was added. The absorbance was measured and the reduction in color intensity was expressed as inhibition percentage. L-ascorbic acid was used as standard antioxidant (positive control). Blank sample was run without ABTS and using MeOH:phosphate buffer (1:1) only [22,23]. The free radical inhibition percentage of each sample was calculated as follows:

\[
\text{ABTS (%inhibition)} = \frac{\text{Abs (control)} - \text{Abs (test)}}{\text{Abs (control)}} \times 100
\]

RESULTS AND DISCUSSION
Cytotoxicity assessment of ZnO and ZnO-CdS nanocomposites, against human tumor cells HePG2, HCT-116, MCF-7, RD, and HeP2

Table 1: In vitro IC₅₀ of ZnO and ZnO-CdS nanocomposites against human tumor cells HePG2, HCT-116, MCF-7, RD and HeP2 compared to doxorubicin

| Compound     | In vitro cytotoxicity IC₅₀ (µg) |
|--------------|---------------------------------|
|              | HePG2  | HCT-116 | MCF-7 | RD    | HeP2   |
| DOX**        | 4.50±0.2 | 5.23±0.3 | 4.17±0.2 | 6.10±0.4 | 8.54±0.6 |
| ZnO          | 33.23±3.2 | 37.09±3.8 | 29.50±2.7 | 47.08±4.1 | 20.53±2.3 |
| ZnO/CdS      | 9.26±1.0 | 5.64±0.4 | 7.90±0.8 | 9.51±0.9 | 10.17±1.1 |

IC₅₀ (µg): 1–10 (very strong), 11–20 (strong), 21–50 (moderate), 51–100 (weak) and above 100 (non-cytotoxic). **DOX: Doxorubicin, ZnO: Zinc oxide, CdS: Cadmium sulfides
The results of Table 1 were indicated that the \textit{in vitro} cytotoxicity $IC_{50}$ (µg/ml) to all five types of tumor cancer was moderate for ZnO NPs, while the \textit{in vitro} cytotoxicity $IC_{50}$ (µg/ml) to HePG2, HCT-116, MCF-7, and RD was very strong and HeP2 was strong for ZnO/CdS nanocomposites [24].

Recent development in cancer research suggests that a number of apoptotic stimuli shares common mechanistic pathway characterized by the generation of ROS. The mechanism of cytotoxicity from ZnO...
NPs is not completely understood. The mechanism of cytotoxicity from ZnO NPs was deepened on the generation of ROS through oxidative stress [22]. ROS typically include the superoxide, the hydrogen peroxide, and the hydroxyl radical which causes damage to cellular component such as lipids, DNA, and proteins and eventually leads to cell death [25]. In agreement with previous reports, it was found that the ZnO NPs induced the generation of ROS in the cancer cells, whereas normal astrocytes exhibited lower levels of ROS in response to the ZnO NPs. Figs. 5-7 demonstrate the relative viability human cancer cells (%) with different concentrations of ZnO NPs and ZnO/CdS nanocomposites, respectively. The results show that the relative viability human cancer cells (%) were decreased with increase of NPs due to the increasing interaction of cancer cell NPs [26].

Table 1 illustrates that the anticancer activity was increased using ZnO/CdS nanocomposites instead of ZnO NPs. This observation can be explained that the band gap energy of ZnO is approximately 3.2 eV [27]. Coupling ZnO particles with narrow bandgap semiconductors such as CdS can be utilized band gap ZnO to visible light. Decreasing of band gap energy causes increasing the ability of NPs to produce ROS which causes damage to cancer cellular components [28].

**Antioxidant activity assessment**

**Free radical scavenging method (ABTS)**
The free radicals of "2, 2-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid)" (ABTS) were used for exposure of the antioxidant activity of ZnO NPs and ZnO/CdS nanocomposites. The decrease in color intensity was expressed as inhibition percentage [29,30]. The lower the percentage inhibition, the higher the antioxidant scavenging activity. The results of antioxidant activity are illustrated in Table 2.

This assay is based on the ability of ABTS to be decolorized in the presence of antioxidants. The corresponding ABTS radical scavenging activity was used for detection of the antioxidant activity. ZnO/CdS nanocomposites was the most active [30]. ZnO NPs caused decreased antioxidant enzyme activities as an antioxidant agent by inhibiting the formation of ROS and scavenging the free radicals [32]. Oxidative stress plays a major role in the etiology of several diabetic complications. NPs are also being explored for use in intracellular delivery of DNA, RNA, proteins, peptides, and small drugs for inducing cancer cell death, as contrast agents for cancer imaging, and as platforms for targeted gene and chemotherapeutics delivery to tumor sites [33]. The results refers the effect of the ZnO NPs on cancer cells results from the ROS generated which leads to an increase sensitivity of these cells to oxidative stress [35,34].

**CONCLUSIONS**

ZnO NPs and ZnO-CdS NPs were synthesized and characterized by various techniques, including XRD, SEM, Fourier-transform infrared and UV-visible (DRS). Anticancer activity and antioxidant activity screening assay ABTS of the NPs were examined using five human cancer cells [HEPG-2, MCF-7, HEP2, HCT-116, and RD]. The effect of the NP concentrations on the cancer cells was determined, and the mechanisms of treatment with the ZnO and ZnO/CdS nanocomposites was depended on the generation of ROS.

**AUTHORS’ CONTRIBUTIONS**

Nicked ZnO NPs and identify this NPs which has been synthesized by Dr. Noor Hadi Ayaa Coupled ZnO/CdS NPs, and identify these NPs which has been synthesized by Dr. Fattima-Alzahara G. Gassiam. Biological activity of two NPs (ZnO and ZnO/CdS) has been done by Dr. Ali J. J. Makkawi, introduction and anticancer results have been written by Dr. Ali J. J. Makkawi, while discussion the results and references have been written by Dr. Fattima-Alzahara G. Gassiam and Dr. Noor Hadi Ayaa.

**CONFLICTS OF INTEREST**

Authors declared no conflicts of interest.

**REFERENCES**

1. Jeong YL, Kim DH, Chung CW, Yoo JJ, Choi KH, Kim CH, et al. Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer. Int J Nanomedicine 2011;6:1415-27.
2. Zheng J, Lee HC, Bin Sattar MM, Huang Y, Bian JS. Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiac injury. Eur J Pharmacol 2011;652:82-8.
3. Liong M, Lu J, Kovovich M, Xia T, Ruehm SG, Nel AE, et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2008;2:889-96.
4. Selvakumari D, Deepa R, Mahalakshmi V, Subbhashini P, Lakshminarayan N. Anticancer activity of ZnO nanoparticles on MCF7 (breast cancer cell) and A549 (cancer cell). ARPN J Eng Appl Sci 2015;10:5418-21.
5. Yousefpour P, Atyabi F, Farahani EV, Sakhiianchi R, Dinarvand R. Polyamionic carbohydrate doxorubicin-dextran nanocomplex as a delivery system for anticancer drugs: In vitro analysis and evaluations. Int J Nanomedicine 2011;6:1487-96.
6. Ibsen S, Zahavy E, Wrudil W, Berns M, Chan M, Esener S, et al. A novel doxorubicin produg with controllable photolysis activation for cancer chemotherapy. Pharm Res 2010;27:1848-60.
7. Chahal A, Saini AK, Kumar A, Saini RV. Natural antioxidants as defense against cancer. Asian J Pharm Res 2018;11:38-44.
8. Mishra PK, Mishra H, Ekielski A, Talegaonkar S, Vaidya B. Zinc oxide nanoparticles: A promising nanomaterial for biomedical applications. Drug Discov Today 2017;22:1825-34.
9. Guo D, Wu C, Jiang H, Li Q, Wang X, Chen B, et al. Synergistic cytotoxic effect of different sized ZnO nanoparticles and daunorubicin against leukemia cancer cells under UV irradiation. J Photochem Photobiol B 2008;93:119-26.
10. Wang H, Wingett D, Engelhard MH, Ferez K, Reddy KM, Turner P, et al. Fluorescent dye encapsulated ZnO particles with cell-specific toxicity for potential use in biomedical applications. J Mater Sci Mater Med 2009;20:11-22.
11. Yadav V. Nanotechnology, big things from a tiny world: A review. Int J Serv Sci Technol 2013;7:37-48.
12. Lin X, Xu Y, Huang CC, Ma Y, Shannon KB, Chen DR, et al. Toxicity of nano- and micro-sized ZnO particles in human lung epithelial cells. J Nanopart Res 2009;11:25-39.
13. Arakelova ER, Grigoryan SG, Arsenyan FG, Bahayan NS, Grigoryan RM, Sarkisyian NK. In vitro and in vivo anticancer activity of nanosize zinc oxide composites of doxorubicin. Int J Biomed Sci 2014;8:11.
14. Litter ML, Navio JA. Un usual photo reactivity of zinc oxide irradiated by concentrated sun light. J Photochem Photobiol A Chem 1994;79:131.
15. Chica A, Gatti G, Moden B, Marchese L, Iglesia E. Selective catalytic oxidation of organosulfur compounds with tert-butil hydroperoxide. Chemistry 2006;12:1960-7.
16. Xin JH, Yeo SY, Lee HJ, Jeong SH. Preparation of nano composite fibres for permanent antibacterial effect. J Mater Sci 2003;38:2143-7.
17. Gnanasangeetha D, Thambwani DS. Biogenic production of zinc oxide nanoparticles: A new organometallic synthetic method. Adv Funct Mater 2005;3:458-68.
18. Spolenak R, Ludwig W, Buffiere JY, Michler J. Textile on antistatic finishing. Int J Chem 2009;1:18-22.
19. Zhang F, Yang J. Preparation of nano-ZnO and its application to the textile on antistatic finishing. Int J Chem 2009;1:18-22.
20. Rasal S, More PV, Hiragond C, Jadhav S, Khanna PK. Rapid homogenization method for synthesis of core/shell ZnO/CdS nanoparticles and their photocatalytic evaluation. Adv Mater Lett 2016;7:390-7.
21. Kahn ML, Monge M. Size-and shape-control of crystalline zinc oxide nanoparticles: A new organometallic synthetic method. Adv Funct Mater 2005;3:458-68.
22. Kavithar R. Antioxidant and enzymatic antioxidant potential from ethanolic extracts of leaf and fruit of Acalypha indica. J Chem Biol Phys Sci 2013;1:238-46.
23. El-Gazar A, Adams B, Youssef YM, Abu-Hashem AA, Badria FA. Design and synthesis of azolopyrimidinoquinolines, pyrimidoquinolines as anti-oxidant, anti-inflammatory and analgesic activities. J Med Chem 2009;44:609-24.
24. Aeschlach R, Lolliger J, Scott CB, Murcia A, Butler JB, Halliwell IO. Antioxidant actions of thymol, carvacrol, 6-geringoler, zingerone and hydroxytyrosol. Food Chem Toxicol 1994;32:31-6.
25. Paš T, Tak ŽY, Song JM. Does the antibacterial activity of silver nanoparticles...
depend on the shape of the nanoparticle? A study of the gram-negative bacterium *Escherichia coli*. Appl Environ Microbiol 2007;73:1712-20.

26. Huang K, Ma H, Liu J, Huo S, Kumar A, Wei T, *et al.* Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano 2012;6:4483-93.

27. Rasmussen JW, Martinez E, Louka P, Wingett DG. Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications. Expert Opin Drug Deliv 2010;7:1063-77.

28. AL-Zahra AF, Alkhateeb A, Hussin F. Photocatalytic oxidation of benzyl alcohol using pure and sensitized anatase. Desalination 2007;209:342-9.

29. AL-Zahra AF, Azize HW, Jassim AJ. Sterilization of waste water from *Staphylococcus aureus* bacteria by using TiO$_2$. Int J Chem 2013;2:386-91.

30. Arya P. Antioxidant, phytochemical and antibacterial action of Himalayan medicinal herbs *Peristrophe bicalyculata* leaves extract against respiratory tract pathogens. Int J Pharm Pharm Sci 2018;10:16-21.

31. Lissi E, Modak B, Torres R, Escobar J, Urza A. Total antioxidant potential of resinous exudates from *Heliotropium* species, and a comparison of the ABTS and DPPH methods. Free Radic Res 1999;30:471-7.

32. Shaaban S, Negm A, Sobh MA, Wessjohann LA. Organoselenocyanates and symmetrical diselenides redox modulators: Design, synthesis and biological evaluation. Eur J Med Chem 2015;97:190-201.

33. Barathmanikanth S, Kalishvaralal K, Sriram M, Pandian SR, Youn HS, Eom S, *et al.* Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice. J Nanobiotechnology 2010;8:16.

34. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649-59.

35. Shaji J, Shaikh M. Drug-resistant tuberculosis: Recent approach in polymer based nanomedicine resistant tuberculosis. Int J Pharm Pharm Sci 2016;8:1-6.